Carperitide
Recombinant human atrial natriuretic peptide used in Japan for acute decompensated heart failure.
Chemical Identity
| Property | Value |
|---|---|
| Chemical Formula | C127H203N45O39S3 |
| Molecular Weight | 3080 Da |
| CAS Number | 89213-87-6 |
| Peptide Class | Recombinant ANP (28 amino acids) |
| Sequence | Human ANP (1-28) |
| Disulfide Bonds | 1 |
Structure
Carperitide is recombinant human atrial natriuretic peptide (ANP), a 28-amino acid peptide with a 17-amino acid ring formed by a disulfide bond between Cys7 and Cys23. It is identical to the endogenous hormone secreted by atrial cardiomyocytes in response to atrial stretch.
Mechanism of Action
Carperitide binds natriuretic peptide receptor A (NPR-A), activating guanylyl cyclase and increasing intracellular cGMP. This causes vasodilation, natriuresis, diuresis, and suppression of the renin-angiotensin-aldosterone system. It reduces both preload and afterload in heart failure.
Clinical Applications
- Acute decompensated heart failure: Approved in Japan (Hanp)
- Pulmonary edema: Rapid hemodynamic improvement
- Perioperative cardiac surgery: Renal protection
- Hypertensive crisis: IV vasodilation
Pharmacokinetics
- Half-life: 2.7 minutes
- Onset: Immediate (IV)
- Duration: 30-60 minutes after infusion
- Metabolism: Neutral endopeptidase and NPR-C clearance
- Route: IV infusion (0.05-0.1 mcg/kg/min)
Safety and Side Effects
Hypotension (dose-limiting), headache, dizziness, and nausea. Careful hemodynamic monitoring required. Primarily used in Japan.
References
- Nomura, F., et al. (1991). Carperitide for heart failure. Japanese Circulation Journal, 55, 409-414.
- Kitashiro, S., et al. (1999). Carperitide in acute heart failure. Journal of Cardiac Failure, 5, 25-31.
Test Your Knowledge
Reinforce what you learned about Carperitide with interactive quizzes on Wikipept.
Take a Quiz on Wikipept